WEST PHARMACEUTICAL SVSC ($WST) posted quarterly earnings results for Q1 2026 on Thursday, April 23rd. The company reported earnings of $2.13 per share, beating estimates of $1.69 by $0.44. The company also reported revenue of $844,900,000, beating estimates of $787,773,376 by $57,126,624.
You can see Quiver Quantitative's $WST stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
WEST PHARMACEUTICAL SVSC Hedge Fund Activity
We have seen 349 institutional investors add shares of WEST PHARMACEUTICAL SVSC stock to their portfolio, and 362 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,635,288 shares (-74.4%) from their portfolio in Q4 2025, for an estimated $725,073,140
- DURABLE CAPITAL PARTNERS LP removed 1,172,583 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $322,624,486
- LONGVIEW PARTNERS (GUERNSEY) LTD added 778,887 shares (+221.2%) to their portfolio in Q4 2025, for an estimated $214,302,969
- VAN ECK ASSOCIATES CORP removed 708,792 shares (-49.7%) from their portfolio in Q4 2025, for an estimated $195,017,030
- GENERATION INVESTMENT MANAGEMENT LLP added 585,855 shares (+60.0%) to their portfolio in Q4 2025, for an estimated $161,192,144
- BROWN ADVISORY INC removed 554,476 shares (-22.2%) from their portfolio in Q4 2025, for an estimated $152,558,526
- CITADEL ADVISORS LLC removed 481,897 shares (-66.2%) from their portfolio in Q4 2025, for an estimated $132,589,140
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
WEST PHARMACEUTICAL SVSC Analyst Ratings
Wall Street analysts have issued reports on $WST in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 10/29/2025
To track analyst ratings and price targets for WEST PHARMACEUTICAL SVSC, check out Quiver Quantitative's $WST forecast page.
WEST PHARMACEUTICAL SVSC Price Targets
Multiple analysts have issued price targets for $WST recently. We have seen 4 analysts offer price targets for $WST in the last 6 months, with a median target of $302.5.
Here are some recent targets:
- Luke Sergott from Barclays set a target price of $275.0 on 04/14/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $320.0 on 02/03/2026
- Kallum Titchmarsh from Morgan Stanley set a target price of $285.0 on 12/02/2025
- Brendan Smith from TD Cowen set a target price of $350.0 on 10/29/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
